<body data-rsssl=1 class=

Letter to Health Care Providers- Important Information on the Use of Serological (Antibody) Tests for COVID-19

The U.S. Food and Drug Administration (FDA) recommends that health care providers continue to use serological tests intended to detect antibodies to SARS-CoV-2 to help identify people who may have been exposed to the SARS-CoV-2 virus or have recovered from the COVID-19 infection. Health care providers should also be aware of the limitations of these

By |2020-09-23T12:08:46+00:00June 29th, 2020|alerts|0 Comments

Education Corner: The Opiod Crisis

CMS, State, and local communities, continue to promote safe and responsible pain management; however, Opioid Use Disorder (OUD), overdoses, and deaths continue to be a growing concern. The following links and tools can help you better understand the current crisis and assist your patients with effective pain management if needed. Pain Management Zone ToolCMS Roadmap:

By |2020-09-23T12:09:03+00:00June 17th, 2020|Uncategorized|0 Comments

5-Diamond Patient Safety COVID-19 Module

A COVID-19 module has been added to the 5 Diamond Patient Safety Program website and is available for any dialysis provider to access. The module was developed in partnership with the American Society of Nephrology (ASN). Objectives for the module include: Discuss COVID-19, including what it is and how it spreads. Identify symptoms of COVID-19. Describe

By |2020-10-14T19:35:17+00:00June 17th, 2020|Uncategorized|0 Comments

Remdesivir by Gilead Sciences: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of Treatment

AUDIENCE: Health Professional, Pharmacy, Patient ISSUE: FDA is warning health care providers that co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended as it may result in reduced antiviral activity of remdesivir. The agency is not aware of instances of this reduced activity occurring in the clinical setting but, is continuing to evaluate all

By |2020-09-23T12:09:36+00:00June 17th, 2020|alerts|0 Comments

Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, Due to Detection of N-Nitrosodimethylamine (NDMA) Impurity

Amneal Pharmaceuticals LLC Bridgewater, New Jersey (Amneal), is voluntarily recalling all lots of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, within expiry to the Retail Level. Amneal was notified by the U.S. FDA that the Agency’s testing of seven lots of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750

By |2020-09-23T12:09:27+00:00June 4th, 2020|alerts|0 Comments